Searching journal content for articles similar to Öberg and Lamberts 23 (12): R551.

Displaying results 1-8 of 8
For checked items
  1. Research:
    • Amira Mohamed,
    • Marie-Pierre Blanchard,
    • Manuela Albertelli,
    • Federica Barbieri,
    • Thierry Brue,
    • Patricia Niccoli,
    • Jean-Robert Delpero,
    • Genevieve Monges,
    • Stephane Garcia,
    • Diego Ferone,
    • Tullio Florio,
    • Alain Enjalbert,
    • Vincent Moutardier,
    • Agnes Schonbrunn,
    • Corinne Gerard,
    • Anne Barlier,
    • and Alexandru Saveanu
    Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures Endocr Relat Cancer 21 (5) 691-704, doi:10.1530/ERC-14-0086 first published on 10 July 2014
    ...of Integrative Biology and Pharmacology, University of Texas, Texas 77225, Houston, USA *(A Saveanu and A Barlier contributed equally to this work) Abstract Gastroenteropancreatic neuroendocrine tumors (GEP–NETs) raise difficult therapeutic problems despite the emergence of targeted therapies. Somatostatin...
  2. Review:
    • Georgios K Dimitriadis,
    • Martin O Weickert,
    • Harpal S Randeva,
    • Gregory Kaltsas,
    • and Ashley Grossman
    Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 23 (9) R423-R436, doi:10.1530/ERC-16-0200 first published on 26 July 2016
    ... M, Annibale B, Moretti A, Silecchia G, Scopinaro F, Basso N, Bordi C, et al. 1998 Use of the somatostatin analogue octreotide to localise and manage R434Review G K Dimitriadis et al. Secretory syndromes in GEP-NETs DOI: 10.1530/ERC-16-0200 http://.endocrinology-journals.org © 2016 Society for Endocrinology...
  3. Thematic Review:
    • Marianne E Pavel and
    • Christine Sers
    WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine Endocr Relat Cancer 23 (11) T135-T154, doi:10.1530/ERC-16-0370 first published on 20 September 2016
    ...but will be generated by an ongoing clinical trial (CLARINET forte, NCT02651987) in progressive GEP-NET. The expression of a truncated splice variant of sstr-5 was associated with poor biochemical response to octreotide in acromegaly (Marina et  al. 2015). The finding that tumor expression of the truncated sstr-5...
  4. Supplement Paper:
    • Kjell Oberg
    Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 18 (S1) S17-S25, doi:10.1530/ERC-10-0280
    ...stimulation, granuleIntroduction The clinical presentation of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) varies according to the site and size of the primary tumour, the presence or absence of metastatic spread, whether associated features compatible with a hereditary syndrome exist or not...
  5. Supplement Paper:
    • Jaap J M Teunissen,
    • Dik J Kwekkeboom,
    • R Valkema,
    • and Eric P Krenning
    Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours Endocr Relat Cancer 18 (S1) S27-S51, doi:10.1530/ERC-10-0282
    ...as the gold standard in nuclear imaging for patients with GEP-NETs (Krenning et al. 1993). The somatostatin analogue octreotide binds with high affinity to receptor subtypes 2 and 5. Several authors demonstrated that a positive [111In-DTPA0]octreotide scintigraphy is mainly due to the sst2, whereas sst1–sst5...
  6. Review:
    • Simona Grozinsky-Glasberg,
    • Ilan Shimon,
    • Márta Korbonits,
    • and Ashley B Grossman
    Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr Relat Cancer 15 (3) 701-720, doi:10.1677/ERC-07-0288 first published on 4 June 2008
    ...–720neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well asREVIEW Somatostatin analogu of neuroendocrine tum and mechanisms Simona Grozinsky-Glasberg1,2, Ilan Sh and Ashley B Grossman1 1Barts and the London School of Medicine, Centre for Endocrinology, Un 2Institute...
  7. Review:
    • Federico Gatto and
    • Leo J Hofland
    The role of somatostatin and dopamine D2 receptors in endocrine tumors Endocr Relat Cancer 18 (6) R233-R251, doi:10.1530/ERC-10-0334
    ...and nonfunctioning NET (Rinke et al. 2009). More in detail, patients with low-grade (Ki-67!2%) and low hepatic tumor load NET, even if non-functioning, are likely to benefit from octreotide treatment as first-line therapy (Rinke et al. 2009). Different from GEP NET, and due to the limited number of clinical studies...
  8. Regular papers:
    • Alexandru Saveanu,
    • Mihaela Muresan,
    • Catherine De Micco,
    • David Taieb,
    • Anne-Laure Germanetti,
    • Frederic Sebag,
    • Jean-François Henry,
    • Laurent Brunaud,
    • Alain Enjalbert,
    • Georges Weryha,
    • and Anne Barlier
    Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas Endocr Relat Cancer 18 (2) 287-300, doi:10.1530/ERC-10-0175 first published on 18 February 2011
    ...(2011) 18 287–300 Introduction adrenal chromaffin cells and extra-adrenal paraganglia respectively (Eisenhofer et al. 2008). These tumorspancreatic neuroendocrine tumors (GEP-NETs). Quantitative RT-PCR of sst1–3 and sst5, D2, NAT, VMAT1/2 was performed in all tumors, while immunohistochemistry analysis...
For checked items

Search Results

New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most